Anifrolumab (Saphnelo) November 30, 2023

November 30, 2023 – Lupus Canada is pleased to share that Anifrolumab (Saphnelo) will be included on the Alberta Drug Benefit List effective December 1st, 2023. For details regarding this listing and renewal criteria, please visit the Alberta Drug Benefit List website.

RAMQ has also included Anifrolumab in their drug formulary update that took effect on November 8th, 2023. For more information please visit www.ramq.gouv.qc.ca/fr/a-propos/liste-medicaments.

Lupus Blog Articles:

The Lupus Canada Annual General Meeting 2026

Read

Lupus Canada Impact Report 2025 | Advocacy, Awareness & Research Outcomes

Read

Mental Health and Lupus: A Global Perspective

Read